Search En menu en ClientConnect
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20180192
    Release date: 2 August 2018

    Promoter – Financial Intermediary




    The project consists of research, development and innovation (RDI) investments related to medical technology in the areas of acute care therapies, surgical workplaces and life science during the 2018-2021 period.


    The operation targets the promoter's RDI activities for the development of new or improved products and technologies that contribute to quality enhancement and cost efficiency in healthcare and life sciences.


    Proposed EIB finance (Approximate amount)

    EUR 180 million

    Total cost (Approximate amount)

    EUR 417 million

    Environmental aspects

    The investments are expected to be carried out in existing facilities, already authorised, and which would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.


    The promoter is a private company not operating in the utilities sector, and is thus not covered by EU directives on procurement.


    Signed - 20/07/2018


    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    Denmark France Germany Sweden Industry